Eloralintide (LY3841136) is EL's amylin analogue answer to NN's Cagrilintide and ZP's Petrelintide. Currently, the only manufacturer I see is Apextide, a tentacle of Sinopep. Any speculation as to when this might surface in the independent research space?
When will Elora make her appearance?
- Thread starter 49metal
- Start date
scarywood75
Scarlett Johansson
Do you mind explaining all the things you mentioned in this post for my lazy ass please ? It sounds very interesting but cagrilintide is the only thing I've recognized
- Joined
- Sep 2, 2024
- Messages
- 1,230
- Reaction score
- 3,232
Translation: Eloralintide is the same type of drug as Cagri. When will we be able to buy Elora from the Chinese?Do you mind explaining all the things you mentioned in this post for my lazy ass please ? It sounds very interesting but cagrilintide is the only thing I've recognized
zpped
Research Enthusiast
Cagrilintide, Petrelintide, and Eloralintide mimic amylin instead of glp1/gip/glucagon.Do you mind explaining all the things you mentioned in this post for my lazy ass please ? It sounds very interesting but cagrilintide is the only thing I've recognized
SinoPep is major fda approved peptide manufacturer
scarywood75
Scarlett Johansson
Oh gotcha, soon hopefully, but it's weird some of the newer drugs are getting there before older ones.
penewbie
Senior Member
If I remember correctly Elora doesn't have all that pH nonsense so... Hopefully sooner rather than later?
(it turns out cagri might also not have that pH nonsense either, but that remains to be confirmed)
(it turns out cagri might also not have that pH nonsense either, but that remains to be confirmed)
leokitcat
New_Member
Does anyone know where the eloralintide / LY3841136 structure could be found? I don’t know how ApexTide is even making it I can’t find anything about the structure online or any research papers on it
This is what I have at hand:
A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With LY3841136 and Tirzepatide, Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes - AdisInsight
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for
adisinsight.springer.com
Attachments
Lullabytreehugger
Member
Someone has done their research very well, good post man! I enjoyed reading up on this new elora and looking forward to its release!
And that's just EL. How many of the dozens of known and unknown candidates will reach approval and in how many years? The answer is: Some of them, someday. I suppose a sound-minded person would wait and concern himself with only such chemicals as reach his apothecary's shelf, but I make no such claim for myself. According, I am seen to poke about in matters that don't rightly concern me.
Last edited:
Well, I'm not unique in being persuaded that something like Tirz/Reta with an amylin receptor agonist may be the best near-term (what is near-term?) combo for weight management. I suspect EL is thinking the same and the strong crowd reports on Tirz/Cagri stacks are compelling. Obviously, CagriSema is barking right up this tree and many are sure to follow.
Last edited:
Lullabytreehugger
Member
Also just a note of caution, from past clinical trials in phase two studies, only about 35% are able to progress to phase three.
Which goes to prove not all new drugs are safe to administer or possible side effects too great or a hundred other reasons for them to fail at phase two.
Now even at phase three progression not all drugs will be cleared for the mass market introduction.
Many drugs/compounds fail this stage for whatever reason it may be unsafe or ineffective or perhaps other sinister findings such as a link to cancers or whatever else they find out.
Clinical studies need a lot of time for this exact reason.
I hope elora passes the challenges it may face and proves to be first and foremost safe and then second effective and third with minimal sides.
The holy trinity of any new drug formulation. Detract from any of the three and you have a failed drug.
Which goes to prove not all new drugs are safe to administer or possible side effects too great or a hundred other reasons for them to fail at phase two.
Now even at phase three progression not all drugs will be cleared for the mass market introduction.
Many drugs/compounds fail this stage for whatever reason it may be unsafe or ineffective or perhaps other sinister findings such as a link to cancers or whatever else they find out.
Clinical studies need a lot of time for this exact reason.
I hope elora passes the challenges it may face and proves to be first and foremost safe and then second effective and third with minimal sides.
The holy trinity of any new drug formulation. Detract from any of the three and you have a failed drug.
Ladylaw
New_Member
I have a friend in the current study. They gave her and kept her on the lowest dose. She experienced extreme fatigue and her weight loss stalled after 3 months. Perhaps there are better results at higher doses.
When you look at all the enduring disquiet surrounding Cagri, one can imagine the troubles any of these AMYR agonists might face. I think we all welcome the vetting of many candidates in the hope that an array of strong options come to retail. In the meantime, we have the field developing daily.
Attachments
Thanks for the info! A LOT of Cagri research includes reports of hard-hitting side effects and varying dose tolerance. I would not be surprised if it comes with the territory on these amylin analogs. I will be very interested to hear how your friend's experience unfolds.
capitallocal787
Registered
This is super helpful! Thank you.
Trending content
-
-
-
-
-
Thread 'Patients scramble as cheaper obesity drug alternatives disappear'
- StopCraving_12
Replies: 58
